Literature DB >> 32213567

TNF-α and IL-10 Control CXCL13 Expression in Human Macrophages.

Nessrine Bellamri1, Roselyne Viel2, Claudie Morzadec1, Valérie Lecureur1, Audrey Joannes1, Bertrand de Latour3, Francisco Llamas-Gutierrez4, Lutz Wollin5, Stéphane Jouneau6,7, Laurent Vernhet8.   

Abstract

The chemokine CXCL13 controls the normal organization of secondary lymphoid tissues and the neogenesis of ectopic lymphoid structures in nonlymphoid organs, particularly the lungs. The progression and severity of idiopathic pulmonary fibrosis (IPF), a fatal and irreversible interstitial lung disease, is predicted by the circulating blood concentrations of CXCL13. Although CXCL13 is produced by pulmonary tissues, it has not been determined which cells are involved. This study examines CXCL13 production by lung tissue macrophages from patients with IPF and the signaling pathways controlling CXCL13 gene expression in human alveolar macrophages (AM) and monocyte-derived macrophages (MoDM). CXCL13 is found in CD68- and CD206-positive AM from patients with IPF, and the CXCL13 gene is induced in these macrophages and MoDM when they are stimulated with LPS. We found that TNF-α and IL-10 control optimal CXCL13 gene expression in MoDM and possibly in AM by activating the NF-κB and JAK/STAT pathways, respectively. We also found that blood TNF-α and CXCL13 concentrations are significantly correlated in patients with IPF, suggesting that TNF-α contributes to CXCL13 production in humans. In conclusion, the results of this study demonstrate that AM from patients with IPF produces CXCL13 and that the NF-κB and JAK/STAT pathways are required to induce the expression of this major chemokine.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Year:  2020        PMID: 32213567     DOI: 10.4049/jimmunol.1900790

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Timing is everything: impact of development, ageing and circadian rhythm on macrophage functions in urinary tract infections.

Authors:  Alison S Wang; Nicholas J Steers; Adwaita R Parab; Frédéric Gachon; Matthew J Sweet; Indira U Mysorekar
Journal:  Mucosal Immunol       Date:  2022-08-29       Impact factor: 8.701

2.  Role of CXCL5 in Regulating Chemotaxis of Innate and Adaptive Leukocytes in Infected Lungs Upon Pulmonary Influenza Infection.

Authors:  Lei Guo; Nan Li; Zening Yang; Heng Li; Huiwen Zheng; Jinxi Yang; Yanli Chen; Xin Zhao; Junjie Mei; Haijing Shi; G Scott Worthen; Longding Liu
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

3.  Interleukin-10-Mediated Lymphopenia Caused by Acute Infection with Foot-and-Mouth Disease Virus in Mice.

Authors:  Zijing Guo; Yin Zhao; Zhidong Zhang; Yanmin Li
Journal:  Viruses       Date:  2021-11-24       Impact factor: 5.048

Review 4.  Role of the CXCL13/CXCR5 Axis in Autoimmune Diseases.

Authors:  Zijian Pan; Tong Zhu; Yanjun Liu; Nannan Zhang
Journal:  Front Immunol       Date:  2022-03-04       Impact factor: 7.561

5.  Innate Immune Anti-Inflammatory Response in Human Spontaneous Intracerebral Hemorrhage.

Authors:  Anan Shtaya; Leslie R Bridges; Rebecca Williams; Sarah Trippier; Liqun Zhang; Anthony C Pereira; James A R Nicoll; Delphine Boche; Atticus H Hainsworth
Journal:  Stroke       Date:  2021-07-20       Impact factor: 7.914

6.  ZFP36 protects lungs from intestinal I/R-induced injury and fibrosis through the CREBBP/p53/p21/Bax pathway.

Authors:  Yongmei Cao; Weifeng Huang; Fang Wu; Jiawei Shang; Feng Ping; Wei Wang; Yingchuan Li; Xuan Zhao; Xiaoping Zhang
Journal:  Cell Death Dis       Date:  2021-07-08       Impact factor: 8.469

Review 7.  STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development.

Authors:  Jessica N Filderman; Mark Appleman; Manoj Chelvanambi; Jennifer L Taylor; Walter J Storkus
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

Review 8.  Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer.

Authors:  Ching-Hung Hsieh; Cheng-Zhe Jian; Liang-In Lin; Guan-Sian Low; Ping-Yun Ou; Chiun Hsu; Da-Liang Ou
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639

Review 9.  CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities.

Authors:  San-Hui Gao; Sheng-Zhi Liu; Gui-Zhen Wang; Guang-Biao Zhou
Journal:  Life (Basel)       Date:  2021-11-23

Review 10.  The Impact of Programmed Cell Death on the Formation of Tertiary Lymphoid Structures.

Authors:  Mélanie Dieudé; Imane Kaci; Marie-Josée Hébert
Journal:  Front Immunol       Date:  2021-07-15       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.